Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).
äŒæ¥ã³ãŒãLLY
äŒç€ŸåEli Lilly and Co
äžå Žæ¥Jul 09, 1970
æé«çµå¶è²¬ä»»è
ãCEOãRicks (David A)
åŸæ¥å¡æ°47000
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jul 09
æ¬ç€Ÿæåšå°Lilly Corporate Ctr
éœåžINDIANAPOLIS
蚌åžååŒæNASDAQ OMX NASDAQ Basic NYSE
åœUnited States of America
éµäŸ¿çªå·46285
é»è©±çªå·13172762000
ãŠã§ããµã€ãhttps://www.lilly.com/
äŒæ¥ã³ãŒãLLY
äžå Žæ¥Jul 09, 1970
æé«çµå¶è²¬ä»»è
ãCEOãRicks (David A)